Comparison of Cabergoline and Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection.

about

Comparison of Cabergoline and Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection.

Item

http://www.wikidata.org/entity/Q48503605

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Comparison of Cabergoline and ...... racytoplasmic Sperm Injection.

@en

Comparison of Cabergoline and ...... racytoplasmic Sperm Injection.

@nl

type

Item

label

Comparison of Cabergoline and ...... racytoplasmic Sperm Injection.

@en

Comparison of Cabergoline and ...... racytoplasmic Sperm Injection.

@nl

prefLabel

Comparison of Cabergoline and ...... racytoplasmic Sperm Injection.

@en

Comparison of Cabergoline and ...... racytoplasmic Sperm Injection.

@nl

P1476

Comparison of Cabergoline and ...... racytoplasmic Sperm Injection.

@en

P2093

Anahita Taheripanah

http://www.w3.org/2001/XMLSchema#string

Mahshid Vasef

http://www.w3.org/2001/XMLSchema#string

Marzieh Zamaniyan

http://www.w3.org/2001/XMLSchema#string

Robabeh Taheripanah

http://www.w3.org/2001/XMLSchema#string

P2860

Cabergoline for preventing ovarian hyperstimulation syndrome

The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.

Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.

Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.

Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study.

Quinagolide--a valuable treatment option for hyperprolactinaemia.

The effectiveness of cabergoline for the prevention of ovarian hyperstimulation syndrome.

Modern management of ovarian hyperstimulation syndrome.

VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status.

Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis.

P304

1-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.22074/IJFS.2018.5259

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29334199

http://www.w3.org/2001/XMLSchema#string

P932

5767925

http://www.w3.org/2001/XMLSchema#string